Printer Friendly

ALLERGAN CONCLUDES SALE OF HUMPHREY DIVISION TO CARL ZEISS

 ALLERGAN CONCLUDES SALE OF HUMPHREY DIVISION TO CARL ZEISS
 IRVINE, Calif., Dec. 4 /PRNewswire/ -- The sale of Allergan Humphrey to Carl Zeiss of Germany, announced Oct. 4, was consummated today following a two-month due-diligence process. The sale provides for an agreement by which Allergan and Carl Zeiss will continue to co-sell phacoemulsification equipment.
 "This transaction represents another step in implementing our strategic realignment," said Allergan Chief Operating Officer William C. Shepherd. "We will continue to build and improve our overall leadership position in eye care by strengthening our prescription, surgical and contact lens care businesses through increased emphasis on R&D and product in-licensing. We also intend to aggressively expand our skin care business by entering additional non-U.S. markets, increasing investment in R&D and Business Development, and accelerating work on our patented retinoids for the topical treatment of psoriasis and acne. We will also maximize the potential for Oculinum/Botox injectable, and look at strategic alliances that will improve any of our existing business or allow us to enter other specialties that complement our core capabilities."
 Allergan Inc. (NYSE: AGN), headquartered in Irvine, is a global provider of specialty therapeutic products, and is expanding beyond skin care and its leadership position in eye care.
 -0- 12/4/91
 /CONTACT: Shel Holtz, 714-752-4387 (office) or 818-366-5296 (home), or Jeff D'Eliscu 714-752-4636 (office) or 714-675-9475 (home), both of Allergan/
 (AGN) CO: Allergan Inc. ST: California IN: MTC SU:


SE -- LA025 -- 9417 12/04/91 17:45 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 4, 1991
Words:247
Previous Article:PEDFA FINANCING WILL HELP CREATE 466 JOBS AND PRESERVE 713 JOBS
Next Article:STOCK CAR RACING CHAMPION DALE EARNHARDT & GILLETTE MAKE ANNOUNCEMENTS AT NASCAR PRESS CONFERENCE
Topics:


Related Articles
CARL ZEISS COMPLETES ACQUISITION OF HUMPHREY OPHTHALMIC INSTRUMENTS
ALLERGAN REPORTS FOURTH QUARTER AND 1991 YEAR END OPERATING RESULTS FOURTH QUARTER EVENTS SUPPORT STRATEGIC DIRECTION FOR THE 1990s
BENSON EYECARE SELLS REMAINING ASSETS OF OPHTHALMIC SURGICAL PRODUCTS DIVISION
Microvision Finalizes Multi-Year Product Development Agreement With Carl Zeiss, Inc.
Zeiss Reports Sales Over 500 Visulas(TM) 690s PDT Lasers Worldwide.
Chabot Space & Science Center Opening Spotlights Evolution of Local Company's Technology.
New President for Carl Zeiss Surgical Products Division.
Carl Zeiss, Inc. Celebrates 75th Anniversary; Dr. Peter Grassmann, Chairman Of the Board, Bids Farewell Upon Retirement.
Breakthrough Medical Device Opens the Door to Better Eye Care.
Carl Zeiss Meditec Launches New Perimetry Product: Humphrey(R) Matrix; New Product Integrates Welch Allyn's Patented Frequency Doubling Technology...

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters